Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191737
Status:
COMPLETED
Last Update Posted:
2007-01-26
First Post:
2005-09-12
Brief Title:
An Open-Label Study of Atomoxetine in Adolescents With Attention-DeficitHyperactivity Disorder
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
An Open-Label Study on Effectiveness and Tolerability of Atomoxetine as Perceived by Patients Parents and Physicians in Adolescents With Attention-DeficitHyperactivity Disorder in Germany
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A single arm open-label phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine given once daily target dose 12 mgkgday as perceived by patients parents and physicians and its impact on self-esteem in adolescents aged 12 through 17 years with Attention-DeficitHyperactivity Disorder treated as outpatients in Germany An 8-week treatment phase is followed by a 16-week extension period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B4Z-SB-LYDE | None | None | None |